Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Medical University of South Carolina
Pfizer
Pfizer
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seoul National University Hospital
Weill Medical College of Cornell University
Mirati Therapeutics Inc.
National Cancer Institute (NCI)